Quantcast
Last updated on April 17, 2014 at 12:35 EDT

Latest Omeprazole Stories

2009-05-06 12:30:00

LAS VEGAS, May 6 /PRNewswire/ -- Results of the Clopidogrel Medco Outcomes Study presented today during SCAI's Annual Scientific Sessions found the anti-clotting benefits of clopidogrel (Plavix) may be reduced when taken concurrently with commonly used heartburn medications called proton pump inhibitors (PPIs). In the study, patients taking clopidogrel and a PPI experienced a: 50% increase in the combined risk of hospitalization for heart attack, stroke, unstable angina, or repeat...

2009-05-04 07:00:00

- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer - WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a product combining low dose aspirin with esomeprazole magnesium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers in patients at risk....

2009-04-23 08:10:30

 In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug."Our results show that proton pump inhibitors are also antiinflammatory agents. They open up an entirely new application...

18af6de42d3bd1b81fbcc64a9d8eb4ab
2009-04-09 07:15:00

The surprising results of a recent study indicate that the decades long medical practice of prescribing heartburn medications to patients with asthma is ineffective. The new study found that the popular heartburn drug Nexium, also known as the purple pill, did not reduce asthma symptoms in patients who were not also suffering from heartburn.  An estimated 2.5 to 5 million suffer from a combination of asthma and gastroesophageal reflux, commonly referred to as heartburn. For at least the...

2009-01-29 08:45:48

Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found (http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001).The study, conducted over 6 years in thousands of heart attack patients aged 66 years and older, found a significantly increased risk of readmission for heart attacks if patients were...

2009-01-23 07:00:00

PITTSBURGH, Jan. 23 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release (DR) Capsules USP, 40 mg, the generic version of AstraZeneca's Prilosec(R) DR Capsules. Omeprazole DR Capsules are indicated for the treatment of peptic ulcers and gastroesophageal reflux disease...

2008-12-19 07:00:00

-Filing also includes age appropriate formulation of 2.5 mg and 5 mg strengths of NEXIUM for Delayed-Release Oral Suspension- WILMINGTON, Del., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages...

2008-10-30 06:00:44

Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 12 at 9:55 a.m. Eastern time (6:55 a.m. Pacific time) at The New York Palace Hotel in New York City. A webcast of the presentation will be available during the event at www.santarus.com and will be archived and available on the Web site for 14 days....

2008-10-01 03:00:07

By Chaudhry, A S Kochhar, R; Kohli, K K Proton pump inhibitors (PPIs) are extensively metabolized in the liver by CYP2C19, that demonstrates genetic polymorphism with 21 mutant alleles. The subjects can be divided into 2 groups with respect to CYP2C19 phenotypes viz., extensive metabolizers (EMs) and poor metabolizers (PMs) of PPIs. This division results in marked interindividual variations in the pharmacokinetics and pharmacodynamics of PPIs in the population. Intragastric pH values and...

2008-09-16 18:00:33

Clopidogrel, a drug used in treating coronary artery disease and marketed as Plavix(R), may be less effective when it interacts with acid reducing proton pump inhibitors (PPIs) (e.g., Prilosec(R), Nexium(R)) according to an Aetna (NYSE:AET) analysis published in the September 16th issue of the Journal of the American College of Cardiology. Initial results showed (a) a one year acute myocardial infarction (MI) of 5.03 percent in the group taking PPIs often; (b) a 3.08 percent one year acute MI...